Small Cell Lung Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Ezabenlimab Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Condition: SCLC Interventions: Drug: PM8002; Drug: Paclitaxel Sponsor: Biotheus Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Ezabenlimab Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Condition: SCLC Interventions: Drug: PM8002; Drug: Paclitaxel Sponsor: Biotheus Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Ezabenlimab Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Condition: SCLC Interventions: Drug: PM8002; Drug: Paclitaxel Sponsor: Biotheus Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Ezabenlimab Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Condition: SCLC Interventions: Drug: PM8002; Drug: Paclitaxel Sponsor: Biotheus Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Ezabenlimab Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Condition: SCLC Interventions: Drug: PM8002; Drug: Paclitaxel Sponsor: Biotheus Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
